Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.KMPH · Entity 5212 | Director · President & CEO | May 25, 2022 | May 26, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date May 25, 2022 · Filed May 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,521 |
Ending reported balance
After 2022-05-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-25 · Purchase · Acquired 2,000 · Balance 38,521 Row 2 · 2022-05-25 · Purchase · Acquired 1,000 · Balance 39,521 |
| Common StockSEC Table I · non-derivative | IndirectBy Mickle Investments LLC | 11,034 |
Reported balance
After 2022-05-25 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-05-25 · Purchase · Acquired 10,000 · Balance 11,034 F1: The Reporting Person is the sole manager member of Mickle Investments, LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy Christal M.M. Mickle 2015 Gift Trust dtd 7/21/15, as trustee | 15,242 |
Reported balance
Holding disclosure · report date 2022-05-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 15,242 |
| Common StockSEC Table I · non-derivative | IndirectBy Travis C. Mickle 2015 Dynasty Trust dtd 7/21/15, Christal M.M. Mickle as trustee | 9,824 |
Reported balance
Holding disclosure · report date 2022-05-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 9,824 |
| Common StockSEC Table I · non-derivative | IndirectBy Mickle Holdings LLC | 96,153 |
Reported balance
Holding disclosure · report date 2022-05-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 96,153 F2: The Reporting Person is the sole manager member of Mickle Holdings, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the sole manager member of Mickle Investments, LLC.
F2: The Reporting Person is the sole manager member of Mickle Holdings, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2022 Filed May 26, 2022 01:03 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 10,000 | $4.39 | $43,900.00 |
DisclosureSEC source: 0001437749-22-013570 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Mickle Investments LLC Disclosed balance after: 11,034 F1 · ownership.nature: The Reporting Person is the sole manager member of Mickle Investments, LLC. Read SEC document |
| May 25, 2022 Filed May 26, 2022 01:03 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,000 | $4.39 | $4,385.00 |
DisclosureSEC source: 0001437749-22-013570 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,521 Read SEC document |
| May 25, 2022 Filed May 26, 2022 01:03 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,000 | $4.36 | $8,711.00 |
DisclosureSEC source: 0001437749-22-013570 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,521 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:12 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 267,156 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001437749-22-002397 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,156 Underlying: Common Stock · 267,156 shares Expires 2032-01-31 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 1, 2023 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 21:03 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,250 | $8.23 | $18,516.38 |
DisclosureSEC source: 0001437749-21-027301 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,521 Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 21:09 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $8.92 | $44,607.50 |
DisclosureSEC source: 0001437749-21-021199 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,271 Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 6,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 8 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: Common stock that was previously held jointly by the Reporting Person and Christal M.M. Mickle, and is now held solely by Ms. Mickle. F4 · ownership.direct: Common stock that was previously held jointly by the Reporting Person and Christal M.M. Mickle, and is now held solely by Ms. Mickle. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 7 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,271 F3 · kind: Transfer of shares to Christal M.M. Mickle. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 1,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 6 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,396 F2 · kind: Transfer of shares held in dissolved trusts to the Reporting Person. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 1,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 5 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C. Mickle & Christal M.M. Mickle TRS UA 4-30-09 TCM Family Trust, co-trustee Disclosed balance after: 0 F2 · kind: Transfer of shares held in dissolved trusts to the Reporting Person. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 7,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 4 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,055 F2 · kind: Transfer of shares held in dissolved trusts to the Reporting Person. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 7,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C. Mickle & Christal M.M. Mickle TRS UA 4-30-09 Mickle Family Trust, co-trustee Disclosed balance after: 0 F2 · kind: Transfer of shares held in dissolved trusts to the Reporting Person. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 96,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Mickle Holdings LLC Disclosed balance after: 96,153 F1 · ownership.nature: The Reporting Person is the sole manager member of Mickle Holdings, LLC. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | OtherCommon Stock | 96,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,354 Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:51 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 263,743 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001437749-21-020865 · rdgdoc.xml · derivative · entry 12 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,743 Underlying: Common Stock · 263,743 shares Expires 2031-08-19 F6 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on August 20, 2022 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 20:37 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,500 | $14.43 | $21,645.00 |
DisclosureSEC source: 0001437749-21-014735 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,507 Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 00:55 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 110,000 | $0.19 | $20,790.00 |
DisclosureSEC source: 0001437749-20-012381 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,888,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,500 | $0.33 | $824.50 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 7 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 4,500 | $0.33 | $1,484.10 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 6 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,775,617 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 3,000 | $0.33 | $989.70 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 5 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 4,500 | $0.33 | $1,501.65 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 4 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,768,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 4,500 | $0.33 | $1,498.50 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,617 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 3,000 | $0.33 | $1,002.30 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,759,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 3,000 | $0.33 | $1,003.20 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,756,117 Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:38 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 420,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002099 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:14 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023640 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $0.79 | $3,938.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 7 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,753,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $0.78 | $3,919.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 6 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,748,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $0.79 | $3,939.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 5 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,743,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $0.80 | $3,976.50 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 4 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,738,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 15,000 | $0.79 | $11,848.50 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $0.78 | $3,921.50 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,718,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 10,000 | $0.78 | $7,839.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,713,117 Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:29 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001437749-19-002182 · rdgdoc.xml · derivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-05 F2 · derivative.exercise_date: Grant to the Reporting Person's spouse of a stock option under the Plan. 25% of the shares will vest on February 6, 2020 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person's spouse is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:29 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 420,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001437749-19-002182 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 6, 2020 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| October 12, 2018 Filed Oct 12, 2018 20:35 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $2.55 | $12,764.00 |
DisclosureSEC source: 0001437749-18-018248 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,703,117 Read SEC document |
| August 30, 2018 Filed Oct 12, 2018 20:35 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 18,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-018248 · rdgdoc.xml · nonDerivative · entry 5 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09 Mickle Family Trust, co-trustee with spouse Disclosed balance after: 123,217 Read SEC document |
| August 30, 2018 Filed Oct 12, 2018 20:35 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 32,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-018248 · rdgdoc.xml · nonDerivative · entry 4 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09 TCM Family Trust, co-trustee with spouse Disclosed balance after: 21,466 Read SEC document |
| August 30, 2018 Filed Oct 12, 2018 20:35 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 18,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-018248 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,698,117 Read SEC document |
| August 30, 2018 Filed Oct 12, 2018 20:35 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 32,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-018248 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,679,978 Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 23:56 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001437749-18-001302 · rdgdoc.xml · derivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-24 F2 · derivative.exercise_date: Grant to the Reporting Person's spouse of a stock option under the Plan. 25% of the shares will vest on January 25, 2019 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person's spouse is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 23:56 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001437749-18-001302 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 25, 2019 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 13:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 8,000 | $3.45 | $27,592.00 |
DisclosureSEC source: 0001437749-17-011578 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Mickle Investments LLC Disclosed balance after: 17,050 F1 · ownership.direct: The Reporting Person and his spouse are the managing members of Mickle Investments, LLC. Read SEC document |
| May 22, 2017 Filed Jun 21, 2017 13:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 18,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-011578 · rdgdoc.xml · nonDerivative · entry 5 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09 Mickle Family Trust, co-trustee with spouse Disclosed balance after: 141,356 Read SEC document |
| May 22, 2017 Filed Jun 21, 2017 13:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 32,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-011578 · rdgdoc.xml · nonDerivative · entry 4 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09 TCM Family Trust, co-trustee with spouse Disclosed balance after: 53,638 Read SEC document |
| May 22, 2017 Filed Jun 21, 2017 13:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 18,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-011578 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,647,806 Read SEC document |
| May 22, 2017 Filed Jun 21, 2017 13:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 32,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-011578 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,629,612 Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 20:29 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,000 | $4.10 | $8,199.00 |
DisclosureSEC source: 0001437749-17-005232 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Mickle Investments LLC Disclosed balance after: 9,050 F1 · ownership.direct: The Reporting Person and his spouse are the managing members of Mickle Investments, LLC. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:53 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001437749-17-001385 · rdgdoc.xml · derivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-26 F2 · derivative.exercise_date: Grant to the Reporting Person's spouse of a stock option under the Plan. 25% of the shares will vest on January 27, 2018 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person's spouse is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:53 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001437749-17-001385 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 27, 2018 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.